Common Contracts
10 similar Underwriting Agreement contracts by Eloxx Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Nevro Corp, others
The Pennant Group, Inc. 3,500,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • October 4th, 2024 • Pennant Group, Inc. • Services-health services • New York
Citigroup Global Markets Inc. Truist Securities, Inc. As Representatives of the several Underwriters, c/o Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013
Apellis Pharmaceuticals, Inc. 8,750,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • November 17th, 2021 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 8,750,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,312,500 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Owens & Minor, Inc. 8,475,000 Shares Common Stock ($2 par value per share) Underwriting AgreementUnderwriting Agreement • October 6th, 2020 • Owens & Minor Inc/Va/ • Wholesale-medical, dental & hospital equipment & supplies • New York
Nevro Corp. Underwriting AgreementUnderwriting Agreement • April 7th, 2020 • Nevro Corp • Surgical & medical instruments & apparatus • New York
Nevro Corp., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), $165,000,000 principal amount of its 2.75% Convertible Senior Notes due 2025 (the “Underwritten Securities”) and, at the option of the Underwriters solely to cover over-allotments, up to an additional $24,750,000 principal amount of its 2.75% Convertible Senior Notes due 2025 (the “Option Securities”) if and to the extent that the Underwriters shall have determined to exercise the option to purchase such Option Securities granted to the Underwriters in Section 2 hereof. The Underwritten Securities and the Option Securities are herein referred to as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.001 per share (the “Common Stock”), or a combination of cash and shares of Common Stock at the Company’s
Apellis Pharmaceuticals, Inc. 9,500,000 Shares Common Stock ($0.0001 par value per share) Underwriting AgreementUnderwriting Agreement • January 9th, 2020 • Apellis Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Apellis Pharmaceuticals, Inc., a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, 9,500,000 shares of common stock, $0.0001 par value per share (“Common Stock”) of the Company (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to 1,425,000 additional shares of Common Stock (the “Option Securities”; the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule I other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Underwriters shall mean either the singular or plural as the contex
Translate Bio, Inc. 9,000,000 Shares Common Stock ($0.001 par value per share) Underwriting AgreementUnderwriting Agreement • September 18th, 2019 • Translate Bio, Inc. • Biological products, (no disgnostic substances) • New York
ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 21st, 2019 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Eloxx Pharmaceuticals, Inc. a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.01 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un
ELOXX PHARMACEUTICALS, INC. 3,333,334 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • June 20th, 2019 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
Eloxx Pharmaceuticals, Inc. a corporation organized under the laws of the State of Delaware (the “Company”), proposes to sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom you (the “Representatives”) are acting as representatives, the number of shares of common stock, $0.01 par value (“Common Stock”) of the Company set forth in Schedule I hereto (said shares to be issued and sold by the Company being hereinafter called the “Underwritten Securities”). The Company also proposes to grant to the Underwriters an option to purchase up to the number of additional shares of Common Stock set forth in Schedule I hereto, if any (the “Option Securities;” the Option Securities, together with the Underwritten Securities, being hereinafter called the “Securities”). To the extent there are no additional Underwriters listed on Schedule II other than you, the term Representatives as used herein shall mean you, as Underwriters, and the terms Representatives and Un
Tocagen Inc. 3,000,000 Shares Common Stock ($0.001 par value) Underwriting AgreementUnderwriting Agreement • December 13th, 2018 • Tocagen Inc • Pharmaceutical preparations • New York
ELOXX PHARMACEUTICALS, INC. 5,130,000 Shares Common Stock ($0.01 par value) Underwriting AgreementUnderwriting Agreement • April 26th, 2018 • Eloxx Pharmaceuticals, Inc. • Services-commercial physical & biological research • New York
